Europe 3D Cell Culture Market Size, Share & Industry Trends Analysis Report by Type (Scaffold-based, Scaffold-free, Microfluidics-based, and Magnetic & Bioprinted), Application, End-user, Country and Growth Forecast, 2022-2028

The Europe 3D Cell Culture Market should witness market growth of 15.2% CAGR during the forecast period (2022-2028).

3D cell cultures are more stable as well as have extended lifespans in contrast to 2D cell cultures. This indicates that they are better ideal for long-term trials and demonstrating the drug's long-term effects. Additionally, 3D surroundings allow cells to grow undisturbed. In 2D, cells must be regularly trypsinized in order to receive enough nutrients for optimal cell development.

Three-dimensional spheroids have been cultivated in the laboratory for up to 302 days while sustaining healthy, noncancerous development. Preclinical testing of the pharmacokinetic and pharmacodynamic effects of medicines and nanomaterials is the main objective of growing cells in 3D scaffolds and also as 3D cell spheroids in vitro.

Toxicology studies have demonstrated that 3D cell cultures are comparable to in vivo studies for assessing the toxicity of medicinal molecules. When comparing LD50 values for six common medications, diclofenac, acetaminophen, amiodarone, metformin, phenformin, and valproic acid, 3D spheroid values correlated directly with in vivo study values.

The industry of research and development in European nations is substantial. Europe comprises 21 OECD countries that are also members of the European Union, as well as Iceland, Norway, and Switzerland, according to the Organization for Economic Co-operation and Development Library. The government's funding for research and development, or GBARD, encompasses both the government's direct R&D and the sums allocated to other institutions for R&D.

The Germany market dominated the Europe 3D Cell Culture Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $212.4 million by 2028. The UK market is anticipated to grow at a CAGR of 14.3% during (2022-2028). Additionally, The France market would exhibit a CAGR of 16% during (2022-2028).

Based on Type, the market is segmented into Scaffold-based, Scaffold-free, Microfluidics-based, and Magnetic & Bioprinted. Based on Application, the market is segmented into Cancer & Stem Cell Research, Drug Discovery & Toxicology Testing, and Tissue Engineering & Regenerative Medicine. Based on End-user, the market is segmented into Pharmaceutical & Biotechnology Companies, Research Institutes, Cosmetic Industry, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Merck Group, Avantor, Inc., Corning Incorporated, Lonza Group AG, Mimetas B.V., Insphero AG, Emulate, Inc., Tecan Group Ltd., and CN Bio Innovations Ltd.

Scope of the Study

By Type

• Scaffold-based
• Scaffold-free
• Microfluidics-based
• Magnetic & Bioprinted

By Application

• Cancer & Stem Cell Research
• Drug Discovery & Toxicology Testing
• Tissue Engineering & Regenerative Medicine

By End-user

• Pharmaceutical & Biotechnology Companies
• Research Institutes
• Cosmetic Industry
• Others

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

• Thermo Fisher Scientific, Inc.
• Merck Group
• Avantor, Inc.
• Corning Incorporated
• Lonza Group AG
• Mimetas B.V.
• Insphero AG
• Emulate, Inc.
• Tecan Group Ltd.
• CN Bio Innovations Ltd.

Unique Offerings

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free